Company: NCEL
Filing Date: 2025-11-06
Form Type: POS AM
Source: 0001213900-25-106799
Chunk: 57

Company: NewcelX Ltd.
Filing Date: 2025-11-06
Form: POS AM
Chunk 57
---
 market -basedmeasurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Annex A-9 NLS PHARMACEUTICS LTD.
NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

As a basis for considering such assumptions there exists a three -tierfair -valuehierarchy, which prioritizes the inputs used in measuring fair value as follows:

| Level 1 — |     | unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.                                                                                                                                                                                                                                                                                                                             |
| Level 2 — |     | pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.                                                                                                                                                                                                                                                                                               |
| Level 3 — |     | pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors. |

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company’s cash and cash equivalents are carried at fair value, determined according to the fair value hierarchy described above. The carrying value of the Company’s accounts payable and accruals approximates fair value due to the short -termnature of these liabilities. The Company did not hold any cash equivalents. Deferred Offering Costs — Equity Line of Credit Deferred offering costs consist of legal, accounting, commitment fees, and other professional fees directly related to anticipated equity financings. Such costs are capitalized until the related equity issuance is completed, at which time they are recorded as a reduction of the offering proceeds. If the planned equity issuance is abandoned or the facility expires without utilization, the costs are expensed in the period of termination. As of June 30, 2025, the Company had recorded $ 296,154in deferred offering costs related to the establishment of its equity line of credit, which had not yet been utilized. The Company had no deferred offering costs outstanding as of June 30, 2024 . Income Taxes The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred